Parapsoriasishttps://en.wikipedia.org/wiki/Parapsoriasis
Parapsoriasis o lo'o fa'atatau i se tasi o fa'alavelave fa'aletonu o le pa'u o lo'o fa'aalia e ala i lo latou foliga e pei o le psoriasis (mumu, manu'a pa'u). O le parapsoriasis o se dermatoses lymphoproliferative e seasea maua e tupu i tagata matutua, 2/3 o ia mea o tane.

E ono tupu mai le kanesa o le pa'u mai le parapsoriasis. Mo se faʻataʻitaʻiga, e mafai ona tupu i le lymphoma T-cell paʻu.

○ Suiga ma Togafitiga
Su'ega toto e fa'asa'o ai le syphilis
Biopsy e taofiofia ai lymphomas paʻu

☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
      References Parapsoriasis-A Diagnosis with an Identity Crisis: A Narrative Review 35426607 
      NIH
      Parapsoriasis is an uncommon inflammatory skin disease characterized by chronic patches that may be resistant to therapy. It was primarily introduced and classified 120 years ago, and the original classification incorporated parapsoriasis and pityriasis lichenoides under the umbrella term parapsoriasis. After a major change in classification, parapsoriasis now exclusively refers to small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP). However, debates still frequently occur regarding various nomenclatures and classifications used by different authors. Moreover, parapsoriasis may progress to overt cutaneous lymphoma, most commonly mycosis fungoides (MF), and it is very difficult to distinguish these two conditions despite modern histologic and molecular testing techniques.
       Histopathologic Evaluation of Parapsoriasis from the Perspective of NB-UVB/PUVA Therapy on the Outcome and Recurrence of the Disease 33911303 
      NIH
      Parapsoriasis, presented as an early stage of cutaneous T-cell lymphoma, is mostly treated with psoralen and ultraviolet A (PUVA) therapy and narrowband ultraviolet B (NB-UVB) phototherapy.